Compliance · The complete guide

IFDA (Iran)

In short

Iran Food and Drug Administration (IFDA — سازمان غذا و دارو — Sazman-e Ghaza va Daru) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME — وزارت بهداشت، درمان و آموزش پزشکی — Vezarat-e Behdasht, Darman va Amuzesh-e Pezeshki) — is the Islamic Republic of Iran's national regulatory authority for human medicines + biologicals + biosimilars + advanced therapy medicinal products + vaccines + medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials across the entire territory of the Islamic Republic of Iran.

Read the full summary

The IFDA operates under the Law on Pharmaceutical Affairs 1334/1955 (قانون مربوط به مقررات امور پزشکی، دارویی و مواد خوراکی و آشامیدنی) + the Food, Drugs and Sanitary Materials Law 1346/1967 + the Law on the Establishment of the Iran Food and Drug Administration 1392/2013 + the Law on Anti-Smuggling of Goods and Currency 1392/2013 + the Counter-Narcotics Law (as amended) + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents + Iranian Pharmacopoeia (Pharmacopoeia Iranica). The IFDA is headquartered in Tehran with substantial regional + provincial Vice-Chancellor for Food and Drug Affairs structures across all 31 Iranian provinces operating through Medical Sciences Universities. The IFDA is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators + is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State (Economic Cooperation Organization) + maintains substantial WHO EMRO + ICH Observer + bilateral cooperation with Russian Roszdravnadzor (substantial EAEU bilateral pharmaceutical-trade) + Chinese NMPA (substantial Belt and Road Initiative pharmaceutical-trade) + Indian CDSCO (substantial pharmaceutical-trade) + Turkish TİTCK (regional EMEA neighbour) + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian (Azerbaijan + Turkmenistan + Tajikistan) regulators reflecting Iran's regional pharmaceutical-trade position. This page covers the IFDA's regulatory architecture for Iranian + foreign manufacturers + sponsors targeting Iran (~88 million population, world's ~21st-largest economy by PPP, substantial regional pharmaceutical-manufacturing hub with ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical; substantial biotechnology + biosimilar industry — Cinnagen is one of the largest biosimilar manufacturers in EMRO; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance challenges; Persian (Farsi) + English overlay labelling, substantial Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability requirements).

3,940 words · ~18 min read

On this page · 9 sections

1What the Iran FDA actually is
2Iranian pharmaceutical regulatory framework
3Drug + biological registration pathways at the IFDA
4IFDA Reference Laboratories + GMP Inspection + PIC/S Member capability
5Medical Device + IVD + Cosmetic + Dietary Supplement Registration
6IFDA Pharmacovigilance + Iranian ADR Centre
7IFDA international engagement
8Common IFDA registration issues + missteps
9How V5 Ultimate supports IFDA readiness

AI · Explain it for MY operation

How does IFDA (Iran) apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your industry

Your scale

01What the Iran FDA actually is

The Iran Food and Drug Administration (IFDA — سازمان غذا و دارو — Sazman-e Ghaza va Daru) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME) — is the Islamic Republic of Iran's national regulatory authority for human medicines + biologicals + biosimilars + advanced therapy medicinal products + vaccines + medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials. The IFDA was established as autonomous deputy organisation under the Law on the Establishment of the Iran Food and Drug Administration 1392/2013 + operates under the Law on Pharmaceutical Affairs 1334/1955 + Food, Drugs and Sanitary Materials Law 1346/1967 + Law on Anti-Smuggling of Goods and Currency 1392/2013 + Counter-Narcotics Law + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents + Iranian Pharmacopoeia.

IFDA organisational structure includes:

Minister of Health and Medical Education (وزیر بهداشت، درمان و آموزش پزشکی) — political head; appointed by the President of the Islamic Republic.
Director-General of the IFDA (رئیس سازمان غذا و دارو) — IFDA head; appointed by the Minister at MoHME Deputy level.
Deputy Directors-General — operational deputies for Pharmaceutical Affairs + Medical Devices + Food + Cosmetics + Inspection + Pharmacovigilance + International Affairs + Administrative Affairs.
Pharmaceutical Affairs Office (اداره کل امور دارو و مواد تحت کنترل) — drug + biological + biosimilar + vaccine + ATMP + generic-medicine registration.
Pharmaceutical Inspection Office (اداره کل بازرسی) — GMP + GDP + GPP + GVP + GLP inspections of Iranian + foreign manufacturing facilities; PIC/S Member capability.
Medical Devices Office (اداره کل تجهیزات پزشکی) — medical-device + IVD registration substantively aligned with EU MDR + IVDR elements.
Pharmacy Practice Office (اداره کل امور داروخانه‌ها) — pharmacy + pharmaceutical-establishment licensing.
Cosmetics + Dietary Supplements Office — cosmetic-product notification + dietary-supplement notification.
Food Office (اداره کل نظارت بر مواد غذایی، آشامیدنی، آرایشی و بهداشتی) — food regulation.
Controlled Substances + Narcotics Office — narcotics + psychotropics framework coordination with INCB + Anti-Narcotics Headquarters + Iranian National Police + Iranian Customs.
Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها — ADR Centre) — WHO PIDM affiliated.
Clinical Trials Office — CTA + Ethics Committee + Medical Sciences University coordination.
Reference Laboratories — IFDA central reference laboratories + Razi Vaccine and Serum Research Institute (Karaj) + Pasteur Institute of Iran (Tehran) substantial vaccine + biological lot-release capacity with ISO/IEC 17025 + WHO PQ-Lab.
International Affairs Office — WHO + ICH + PIC/S + WHO EMRO + ECO + Roszdravnadzor + NMPA + CDSCO + TİTCK + bilateral coordination.
Provincial Vice-Chancellor for Food and Drug Affairs (معاونت غذا و دارو) — 31 provinces, operating through Medical Sciences Universities for inspection + pharmacovigilance + provincial pharmaceutical-establishment regulation.

Iran's distinctive regional pharmaceutical-hub context: Iran is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators. The Islamic Republic of Iran is a substantial regional pharmaceutical-manufacturing hub with ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically. Iran has substantial biotechnology + biosimilar industry — Cinnagen (headquartered in Tehran) is one of the largest biosimilar manufacturers in EMRO + one of the substantial global biosimilar manufacturers; AryoGen Pharmed + Pooyesh Darou + Samenpharmed + Orchid Pharmed substantial biosimilar + biotechnology capacity. Iran has substantial vaccine-manufacturing capacity via Razi Vaccine and Serum Research Institute (Karaj — historical animal + human vaccine production) + Pasteur Institute of Iran (Tehran — substantial human vaccine + biological production including BCG + DTP + measles + rubella + hepatitis B + COVID-19 vaccines). Iran is uniquely positioned by substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance challenges driving substantial domestic-manufacturing self-sufficiency policy + EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Central Asia trade-partner reorientation. Iran's geographic + economic position at the crossroads of the Middle East + Central Asia + South Asia + Caucasus makes it operationally significant for foreign manufacturers + sponsors targeting EMRO + EAEU + Central Asian markets via sanctions-compliant pathways.

IFDA is distinct from + complementary to: the Iran Pharmacists Association (Anjoman-e Daru-sazan-e Iran — professional licensing body for individual pharmacists); the Iranian Medical Council (Nezam-e Pezeshki — physician + dentist + pharmacist + other-healthcare-professional licensing); the Syndicate of Iranian Pharmaceutical Industries (representing manufacturers); the Iranian Generic Pharmaceutical Manufacturers Association; the Anti-Narcotics Headquarters (Setad-e Mobarezeh ba Mavadd-e Mokhader); the Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance pharmaceutical-reimbursement coordination; and substantial Iranian biopharmaceutical-research infrastructure including Tehran University of Medical Sciences + Shahid Beheshti University of Medical Sciences + Isfahan University of Medical Sciences + Mashhad University of Medical Sciences + Shiraz University of Medical Sciences + Tabriz University of Medical Sciences + Iran University of Medical Sciences + Royan Institute (stem cell + reproductive biology) + Pasteur Institute + Razi Institute. Iran's pharmaceutical environment is uniquely characterised by: substantial regional pharmaceutical-manufacturing hub status with ~97% domestic-volume self-sufficiency; substantial biotechnology + biosimilar industry led by Cinnagen + AryoGen; substantial vaccine-manufacturing capacity via Razi + Pasteur Institutes; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses; PIC/S Member status (since 2018) enabling substantial mutual-recognition; substantial WHO PQ programme participation; substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Afghan + Central Asian + Caucasus trade-partner reliance; substantial Climate Zone II coastal Caspian (Rasht + Sari + Anzali) + Persian Gulf (Bushehr + Bandar Abbas + Ahvaz) + IVa interior (Tehran + Isfahan + Shiraz + Mashhad + Tabriz) + IVb arid Central Plateau (Yazd + Kerman + Zahedan + Birjand) stability requirements; Persian (Farsi) labelling.

IFDA is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State + maintains substantial WHO EMRO + ICH Observer + bilateral cooperation with Russian Roszdravnadzor (substantial EAEU bilateral pharmaceutical-trade) + Chinese NMPA (substantial Belt and Road Initiative pharmaceutical-trade) + Indian CDSCO (substantial pharmaceutical-trade) + Turkish TİTCK (regional EMEA neighbour + PIC/S Member peer) + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian (Azerbaijan + Turkmenistan + Tajikistan) regulators reflecting Iran's regional pharmaceutical-trade position + sanctions-environment supply-chain reorientation.

One sentence summary

Iran IFDA is the Islamic Republic of Iran's pharmaceutical + medical-device + cosmetic + dietary-supplement + food + pharmacy regulator operating as autonomous deputy organisation of MoHME under the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955; is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators; is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State + substantial regional pharmaceutical-manufacturing hub serving Iran (~88 million population, world's ~21st-largest economy by PPP, ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical, substantial biotechnology + biosimilar industry led by Cinnagen one of the largest EMRO biosimilar manufacturers, substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions with humanitarian-exemption General Licenses, substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Central Asia trade-partner reliance, Persian (Farsi) labelling, Climate Zone II coastal + IVa interior + IVb arid stability requirements).

02Iranian pharmaceutical regulatory framework

Iranian pharmaceutical regulation operates under a layered framework of Laws + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents — incorporating substantial PIC/S GMP + ICH guideline + WHO TRS Annex elements:

Law on the Establishment of the Iran Food and Drug Administration 1392/2013 — IFDA establishment as autonomous deputy organisation of MoHME.
Law on Pharmaceutical Affairs 1334/1955 (قانون مربوط به مقررات امور پزشکی، دارویی و مواد خوراکی و آشامیدنی) — foundational pharmaceutical law.
Food, Drugs and Sanitary Materials Law 1346/1967 — overarching food + drug + sanitary-materials framework.
Law on Anti-Smuggling of Goods and Currency 1392/2013 — substantive anti-counterfeit + anti-smuggling enforcement framework.
Counter-Narcotics Law (as amended) — narcotics + psychotropics framework.
IFDA Drug Registration Regulation — substantive drug registration framework.
IFDA Medical Device Regulation — substantively incorporating EU MDR + IVDR + IMDRF elements.
IFDA Cosmetics Regulation — substantively incorporating EU Cosmetics Regulation elements.
IFDA GMP Guide — substantively aligned with PIC/S GMP Guide + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements.
IFDA GDP Guide — substantively aligned with WHO GDP + EU GDP elements.
IFDA GCP Guide — substantively aligned with ICH E6(R2).
IFDA GVP Guide — substantively aligned with ICH E2 + WHO PV guidance + EU GVP elements.
Pharmacopoeia recognition — Iranian Pharmacopoeia (Pharmacopoeia Iranica) + recognises European Pharmacopoeia + British Pharmacopoeia + USP + Indian Pharmacopoeia + Russian Pharmacopoeia + Chinese Pharmacopoeia.
Iranian National Essential Medicines List (IRNL — فهرست رسمی داروهای ایران) — substantively aligned with WHO Essential Medicines List + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance Reimbursement List.
Variations + 5-year Drug Registration Renewal framework.
Pricing Decree — substantive pricing-control framework via IFDA Pricing Commission + reference-pricing methodology.
Sanctions Environment Operational Framework — substantial sanctions-environment compliance framework under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance.
Local-Industry-Protected Status Framework — distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist.

03Drug + biological registration pathways at the IFDA

Pathway	Use case	Clock + content
New Drug Registration	First-in-Iran new chemical entity / new biological / new indication; full IFDA Pharmaceutical Affairs Office scientific review + Drug Registration Commission opinion + GMP inspection where required.	IFDA target review: 270-360 calendar days for new drug registration; subject to clock-stops for company-response.
Generic Drug Registration	Generic version of registered Reference Drug; bioequivalence study where required per IFDA BE Guidance.	IFDA target review: 180-270 calendar days for generic registration; substantially reduced for EMA + SRA-approved generics.
Biosimilar Registration	Biosimilar version of registered reference biological; per IFDA + EMA biosimilar guidance; substantial Iranian biosimilar-industry context with Cinnagen + AryoGen leadership.	IFDA target review: 270-360 calendar days; comparability + clinical pathway substantively aligned with EMA + WHO biosimilar guidance.
Vaccine Registration	Vaccines for human use including Iranian National Immunisation Programme + travel + pandemic vaccines; substantial Iranian-domestic vaccine-manufacturing capacity via Razi + Pasteur Institutes.	IFDA target review: 180-360 calendar days; EMA + WHO PQ + Chinese NMPA + Russian Roszdravnadzor + Indian CDSCO reliance accepted; substantial Iranian-domestic vaccine-manufacturing capacity.
ATMP Registration	Advanced Therapy Medicinal Products (gene therapy, cell therapy, tissue-engineered products); per IFDA + EMA + Royan Institute ATMP guidance; substantial Iranian stem-cell + cell-therapy research capacity.	IFDA target review: 270-360 calendar days; comparability + clinical pathway substantively aligned with EMA ATMP framework.
SRA + WHO PQ Reliance	Reliance on EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS + WHO PQ decisions; subject to sanctions-environment compliance.	IFDA target review: substantially reduced timeline for SRA + WHO PQ-approved products subject to sanctions-environment compliance.
WHO PQ Programme Participation	Iranian-manufactured medicines + vaccines + biosimilars submitted to WHO PQ for substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines.	Substantial Iranian-domestic manufacturer WHO PQ engagement for UN-agency humanitarian procurement opportunities.
Local-Industry-Protected Status Pathway	Distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist + supporting Iranian-domestic manufacturing investment + technology transfer.	IFDA + Syndicate of Iranian Pharmaceutical Industries coordinated review; substantial preferential treatment for Iranian-localised products.
Trade-Partner Reliance	Substantial trade-partner reliance pathways with Russian Roszdravnadzor + Chinese NMPA + Indian CDSCO + Turkish TİTCK + Pakistani DRAP reflecting sanctions-environment trade-partner reorientation.	IFDA target review: substantially reduced timeline for trade-partner approved products under bilateral arrangements.
Variations + 5-year Renewal	Variations + mandatory 5-year renewal of registration.	Variations 30-180 calendar days; renewal 90-180 calendar days.
Clinical Trial Application (CTA)	Iranian clinical trials require IFDA CTA + Ethics Committee approval + Medical Sciences University coordination + GCP compliance; substantial Iranian academic-medical-centre clinical-research capacity.	IFDA target review: 60-90 calendar days for CTA; substantial Iranian clinical-trials hub role + biosimilar comparability-trial capacity.
Compassionate Use + Named Patient	Compassionate-use + named-patient access frameworks for unmet-medical-need patients per IFDA guidance.	Expedited IFDA review on case-by-case basis.
Orphan Drug Designation	IFDA orphan-drug designation framework substantively aligned with EMA orphan-drug framework.	IFDA designation review with substantial regulatory + reimbursement benefits.
Pricing + Insurance Reimbursement Coordination	Pricing-control framework via IFDA Pricing Commission + reference-pricing methodology + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance Reimbursement Commission coordination.	Parallel pricing + reimbursement review post-registration; substantial Iranian-localised + WHO PQ preferential treatment.

04IFDA Reference Laboratories + GMP Inspection + PIC/S Member capability

IFDA Reference Laboratories include the IFDA central reference laboratories + Razi Vaccine and Serum Research Institute (Karaj — substantial vaccine lot-release + biological QC capacity) + Pasteur Institute of Iran (Tehran — substantial vaccine + biological + diagnostics capacity) with substantial ISO/IEC 17025 + WHO PQ-Lab capacity. IFDA is a PIC/S Member (since 2018) enabling substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance. The IFDA Pharmaceutical Inspection Office conducts substantial inspections of Iranian-domestic + foreign manufacturing facilities both domestically + via PIC/S mutual-recognition + bilateral arrangements.

ISO/IEC 17025 — IFDA Reference Laboratories + Razi Institute + Pasteur Institute operate with substantial ISO/IEC 17025 accredited scope.
WHO PQ-Lab — Razi Institute + Pasteur Institute + IFDA Reference Laboratories WHO PQ-Lab participating; substantial WHO PQ programme participation.
PIC/S Member (since 2018) — substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance; one of the most operationally significant IFDA capabilities for foreign-manufacturer GMP-inspection coordination.
Vaccine lot release — Razi Institute (Karaj) + Pasteur Institute of Iran (Tehran) substantial vaccine lot-release testing for Iranian National Immunisation Programme + substantial Iranian-domestic vaccine-manufacturing capacity + WHO PQ programme.
Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + targeted enforcement testing.
Medical-device + IVD testing — pre-market + post-market quality testing.
Cosmetic-product + dietary-supplement + food testing — safety + ingredient compliance testing.
Counterfeit-medicine forensics — substantial forensic analytical support for IFDA + Iranian National Police + Iranian Customs + WHO Global Surveillance & Monitoring System contributions; substantial counterfeit-medicine quality risk given sanctions-environment supply-chain disruption + cross-border smuggling.
Substantial biosimilar QC capacity — substantial Iranian biosimilar-industry QC capacity supporting Cinnagen + AryoGen + Pooyesh Darou + Samenpharmed + Orchid Pharmed biosimilar comparability + characterisation + lot-release.
Capacity-building — substantial WHO + bilateral-donor capacity-building programmes + training for Iranian pharmaceutical analysts.
GMP Inspectorate — substantial PIC/S Member capability for Iranian + foreign manufacturing facility GMP inspections both domestically + via PIC/S mutual-recognition + bilateral arrangements; substantial export-market support for ~120+ Iranian-domestic manufacturers including biosimilar + vaccine + generic capacity.
Iranian domestic manufacturer support — supports substantial Iranian-domestic pharmaceutical-manufacturing industry including ~120+ manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical.

05Medical Device + IVD + Cosmetic + Dietary Supplement Registration

IFDA medical-device + IVD regulation operates under IFDA Medical Device Regulation substantively incorporating EU MDR 2017/745 + IVDR 2017/746 + IMDRF elements. Iran has substantial medical-device-manufacturing capacity with ~80+ Iranian-domestic medical-device manufacturers covering substantial portions of domestic consumption + regional EMRO + Central Asian + EAEU export markets.

Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR; IVDs classified under separate framework substantively aligned with EU IVDR.
Iranian Authorised Representative — Iran-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + IFDA regulatory interface.
ISO 13485:2016 — recognised by IFDA as QMS evidence framework; substantial Iranian-domestic manufacturer ISO 13485 capacity.
Reliance pathways — IFDA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan + Russian + Chinese + Indian + Turkish-approval evidence as supporting evidence subject to sanctions-environment compliance; CE Mark + Russian + Chinese substantially central given EAEU + Belt and Road operational context.
Post-market vigilance — IFDA operates medical-device adverse-event reporting; reporting timelines substantively aligned with EU MDR + IMDRF Adverse Event Reporting Codes.
IVD Reactivigilance — IFDA operates IVD reactivigilance reflecting Iran's substantial clinical-laboratory infrastructure including academic-medical-centres + Medical Sciences University-affiliated hospitals.
Cosmetic Notification — cosmetics require IFDA Cosmetic Notification + Persian labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU Cosmetics Regulation elements-aligned framework.
Dietary Supplement Registration — IFDA Dietary Supplements framework.
Traditional + Complementary Medicines — distinctive Iranian traditional Persian medicine (طب سنتی ایرانی) framework recognising substantial Iranian-traditional-medicine heritage including substantial Avicennian medical heritage.
Substantial Export-Market Support — IFDA provides substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan African markets via GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product issuance.

06IFDA Pharmacovigilance + Iranian ADR Centre

IFDA operates the Iranian Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها — ADR Centre). Iran is a WHO Programme for International Drug Monitoring (PIDM) member + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Iranian ADR Centre coordinates with Medical Sciences Universities + academic-medical-centres + Iran Pharmacists Association + Iranian Medical Council + Marketing Authorisation Holders. Iranian pharmacovigilance is uniquely shaped by substantial regional pharmaceutical-hub status + substantial biosimilar + biotechnology + vaccine surveillance commitments + substantial sanctions-environment supply-chain quality-risk monitoring + substantial 31-province Vice-Chancellor for Food and Drug Affairs provincial network.

Iranian Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها) — coordinated by IFDA.
WHO PIDM Member — Iran contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
Iranian PV Network — coordinated national network with effector centres in major Iranian Medical Sciences Universities (Tehran + Shahid Beheshti + Iran + Isfahan + Mashhad + Shiraz + Tabriz + Ahvaz Jundishapur + Kerman + Mazandaran + Guilan + Zahedan + Kermanshah + Yazd + Hamadan + Qazvin + Babol + Ardabil + Birjand + Bandar Abbas + Ilam + Lorestan + Sanandaj + Semnan + Urmia + 31-province Vice-Chancellor for Food and Drug Affairs structures) + Iran Pharmacists Association + Marketing Authorisation Holders.
ADR Reporting — IFDA operates ADR reporting via Iranian Pharmacovigilance Centre portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
E2B(R3) ICSR — IFDA accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
Risk Management Plans (RMP) — IFDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + ATMPs + high-risk products; substantial Iranian biosimilar Risk Management Plan capacity.
Active surveillance — Iranian Pharmacovigilance Centre operates substantial active-surveillance programmes for COVID-19 vaccines + childhood immunisation + biosimilars + ATMPs + high-risk products including substantial Iranian-domestic COVID-19 vaccine surveillance.
AEFI Surveillance — Iranian vaccine adverse-event surveillance aligned with WHO methodology; central to Iranian National Immunisation Programme + substantial Razi + Pasteur Institute vaccine programmes + UNICEF + WHO-supported immunisation campaigns.
Matériovigilance + Cosmétovigilance — IFDA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
Counterfeit + substandard medicine surveillance — substantial role given Iran's sanctions-environment supply-chain disruption + cross-border smuggling + regional Afghan + Iraqi + Pakistani border-trade quality risks.
PIC/S Mutual-Recognition — substantial PIC/S Member pharmacovigilance + GMP-inspection mutual-recognition subject to sanctions-environment compliance.
Biosimilar Pharmacovigilance — substantial Iranian biosimilar-industry pharmacovigilance commitments supporting Cinnagen + AryoGen + Pooyesh Darou + Samenpharmed + Orchid Pharmed biosimilar post-market surveillance.

07IFDA international engagement

PIC/S Member (since 2018) — one of the most operationally significant IFDA capabilities; substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance.
WHO PIDM Member — Iran contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
WHO PQ Programme Participant — Iran-manufactured medicines + vaccines + biosimilars via WHO PQ enable substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institute vaccines.
WHO EMRO — substantial WHO Eastern Mediterranean Regional Office cooperation; substantial regional pharmaceutical regulatory cooperation.
ECO Member State — Economic Cooperation Organization (10 Member States — Iran + Türkiye + Pakistan + Afghanistan + Azerbaijan + Kazakhstan + Kyrgyzstan + Tajikistan + Turkmenistan + Uzbekistan); substantial regional ECO pharmaceutical regulatory cooperation.
ICH Observer — substantial ICH guideline implementation in Iranian regulatory practice including ICH Q1-Q14 + E1-E20 + M1-M11 + S1-S12.
Russian Roszdravnadzor Bilateral — substantial EAEU + neighbour bilateral cooperation reflecting Iran-Russia pharmaceutical-trade growth + sanctions-environment EAEU pharmaceutical-import opportunity.
Chinese NMPA Bilateral — Belt and Road Initiative substantial bilateral pharmaceutical cooperation + substantial China-Iran pharmaceutical + API trade reflecting sanctions-environment supply-chain reorientation.
Indian CDSCO Bilateral — substantial trade-driven cooperation reflecting India as substantial pharmaceutical + API import source for Iran.
Turkish TİTCK Bilateral — regional EMEA neighbour + substantial bilateral cooperation reflecting Iran-Türkiye pharmaceutical-trade + PIC/S Member peer cooperation.
Iraqi MoH + Syrian MoH Bilateral — substantial bilateral cooperation reflecting Iran-Iraq + Iran-Syria pharmaceutical-trade; Iran is one of the largest pharmaceutical export sources to Iraq + Syria.
Pakistani DRAP + Afghan MoPH Bilateral — substantial regional bilateral cooperation reflecting cross-border pharmaceutical-trade + humanitarian operations.
Central Asian + Caucasus Regulators Bilateral — substantial bilateral cooperation with Azerbaijan + Turkmenistan + Tajikistan reflecting Iran's regional pharmaceutical export hub role.
ICDRA + EMRO + IMDRF + IPRP participation — substantial International Conference of Drug Regulatory Authorities + WHO EMRO + International Medical Device Regulators Forum + International Pharmaceutical Regulators Programme participation.
International Generic and Biosimilar Medicines Association (IGBA) — substantial international generic + biosimilar cooperation reflecting Iran's substantial biosimilar industry.
Donor + Bilateral Cooperation — substantial bilateral cooperation with WHO + UNICEF + UN-agency humanitarian programmes + bilateral pharmaceutical-regulatory + healthcare programming subject to sanctions-environment compliance.

08Common IFDA registration issues + missteps

Sanctions-environment compliance under-planned — most operationally significant feature of Iranian pharmaceutical market access; substantial US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance frequently under-planned by foreign manufacturers leading to substantial transactional + financial-channel + insurance + shipping + banking compliance failures.
PIC/S Member (since 2018) mutual-recognition under-leveraged — substantial PIC/S Member mutual-recognition substantially under-leveraged for GMP-inspection coordination subject to sanctions-environment compliance.
Iranian Authorised Representative not properly designated — application rejected at IFDA intake or post-approval compliance failure; Iranian Authorised Representative must be Iran-resident legal entity with appropriate licensure.
Persian (Farsi) labelling deficiencies — Persian required; many applicants provide insufficient Persian-language patient leaflet content.
IFDA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Iran-specific IFDA GMP clarifications.
Iran climate-zone stability data missing — Iran spans Climate Zone II coastal Caspian (Rasht + Sari + Anzali) + Persian Gulf (Bushehr + Bandar Abbas + Ahvaz) + IVa interior (Tehran + Isfahan + Shiraz + Mashhad + Tabriz) + IVb arid Central Plateau (Yazd + Kerman + Zahedan + Birjand); requires substantial zonal-specific stability data.
Local-Industry-Protected Status not addressed — distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist; substantial Iranian-localised manufacturing investment + technology transfer + joint-venture pathways frequently under-leveraged.
Pricing + Insurance Reimbursement Coordination not planned — parallel pricing + reimbursement review post-registration via Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance frequently under-planned.
WHO PQ programme opportunity not leveraged — Iranian-domestic manufacturers notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines can leverage substantial WHO PQ programme participation for UN-agency humanitarian procurement + LMIC market access.
EMA + SRA + WHO PQ reliance under-utilised — substantial EMA + Stringent Regulatory Authority + WHO PQ reliance substantially under-utilised subject to sanctions-environment compliance.
Trade-partner reliance (Roszdravnadzor / NMPA / CDSCO / TİTCK / DRAP) under-utilised — substantial trade-driven reliance reflecting Iran's substantial sanctions-environment supply-chain reorientation to EAEU + Belt and Road + India + Türkiye + Pakistan + Afghanistan + Central Asian trade partners frequently under-utilised.
Bioequivalence centres + biowaiver — IFDA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
Counterfeit + substandard medicine quality risks under-monitored — Iran's sanctions-environment supply-chain disruption + cross-border Afghan + Iraqi + Pakistani border-trade smuggling create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance.
Substantial Iranian export-market support not leveraged — substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product capacity substantially under-leveraged for foreign-manufacturer Iranian-localised production + EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa export markets.
Substantial Iranian biosimilar + biotechnology + vaccine + Royan Institute ATMP + Pasteur Institute + Razi Institute innovation industry partnership opportunities not leveraged — substantial Iranian biosimilar + biotechnology + vaccine + ATMP innovation industry partnership opportunities substantially under-leveraged.
Substantial Iranian academic-medical-centre clinical-research capacity not leveraged — substantial 88-million-population + 31-province Medical Sciences Universities clinical-research capacity substantially under-leveraged.
Variations strategy not planned — variations procedure with Iran-specific timelines + fee structure.
Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

09How V5 Ultimate supports IFDA readiness

V5 Ultimate provides the operational infrastructure Iranian + foreign-supplier sites need for the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955 + IFDA Drug Registration Regulation + IFDA GMP + IFDA Medical Device Regulation + IFDA Cosmetics Regulation + PIC/S Member mutual-recognition + WHO PQ programme participation + WHO EMRO + ECO + Iranian Pharmacovigilance Centre + substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa markets + substantial sanctions-environment compliance support.

IFDA GMP control framework — PIC/S + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements-aligned controls with ALCOA+ data-integrity + Iran-specific clarifications + Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability monitoring.
IFDA registration dossier packaging — Iran CTD-aligned dossier structure with Iran Module 1 specifics + Module 3 stability + Persian patient leaflet + Iranian Authorised Representative declarations + IFDA Drug Registration Regulation framework + substantial EU Module reuse.
Sanctions-environment compliance workflow — most operationally significant feature; substantial US OFAC + EU + UK OFSI sanctions-environment compliance packaging including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance + insurance + shipping + banking compliance support.
PIC/S Member mutual-recognition workflow — substantial PIC/S Member mutual-recognition packaging for GMP-inspection coordination subject to sanctions-environment compliance.
WHO PQ programme workflow — Iranian-manufactured medicines + vaccines + biosimilars WHO PQ submission packaging for substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines.
EMA + SRA + WHO PQ reliance workflow — IFDA-EMA + IFDA-FDA + IFDA-Health Canada + TGA + Swissmedic + MHRA + MFDS + PMDA + WHO PQ reliance packaging subject to sanctions-environment compliance.
Local-Industry-Protected Status workflow — distinctive Iranian-domestic pharmaceutical-manufacturing localisation packaging + Iranian-localised manufacturing investment + technology transfer + joint-venture pathway support.
Pricing + Insurance Reimbursement Coordination workflow — IFDA Pricing Commission + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance coordination packaging for parallel pricing + reimbursement review post-registration.
Trade-partner reliance workflow (Roszdravnadzor / NMPA / CDSCO / TİTCK / DRAP) — substantial sanctions-environment trade-partner reliance packaging reflecting Iran's substantial supply-chain reorientation to EAEU + Belt and Road + India + Türkiye + Pakistan + Afghanistan + Central Asian trade partners.
Iranian Authorised Representative workflow — foreign-manufacturer Iranian Authorised Representative designation + role-management + Iran-specific post-market surveillance.
Iranian clinical-trial workflow — IFDA CTA + Tehran + Shahid Beheshti + Iran + Isfahan + Mashhad + Shiraz + Tabriz / Royan Institute / Pasteur Institute / Razi Institute Medical Sciences University Ethics Committee coordination + Iranian SUSAR reporting via Iranian Pharmacovigilance Centre; substantial Iranian clinical-trials hub role + biosimilar comparability-trial capacity.
Iranian Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Iranian ICSR + Iranian PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + substantial biosimilar pharmacovigilance commitments.
Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
Medical-device + IVD + cosmetic + dietary-supplement + traditional-Persian-medicine workflow — IFDA frameworks dossier packaging + Class I-III classification + ISO 13485 + Iranian Authorised Representative + post-market vigilance.
Counterfeit + substandard medicine surveillance workflow — Iran's sanctions-environment supply-chain disruption + cross-border Afghan + Iraqi + Pakistani border-trade quality-risk monitoring + WHO Global Surveillance & Monitoring System integration.
Biosimilar + ATMP workflow — IFDA biosimilar + ATMP registration packaging substantively aligned with EMA + Royan Institute frameworks; substantial Iranian biosimilar + Royan Institute ATMP-innovation industry support.
Vaccine + Razi + Pasteur Institute workflow — substantial Iranian vaccine-manufacturing capacity packaging including Razi Institute (Karaj) + Pasteur Institute of Iran (Tehran) + Iranian National Immunisation Programme support.
Iranian export-market support workflow — substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product capacity packaging for foreign-manufacturer Iranian-localised production + EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa export markets.
EMRO + Central Asian + EAEU + Belt and Road regional bridging — for companies operating across EMRO + Central Asian + EAEU + Belt and Road jurisdictions, V5 surfaces IFDA + Iraq MoH + Syria MoH + Türkiye TİTCK + Pakistan DRAP + Afghan MoPH + Roszdravnadzor + NMPA + CDSCO + Central Asian harmonised dossier-element reuse alongside national-specific extensions + sanctions-environment compliance.

Frequently asked questions

Q.What does the Iran FDA regulate?+

The Iran Food and Drug Administration (IFDA — سازمان غذا و دارو) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME) — is the Islamic Republic of Iran's national regulatory authority for human medicines (drugs, biologicals, biosimilars, vaccines, ATMPs), medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials under the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955 + Food, Drugs and Sanitary Materials Law 1346/1967. The IFDA operates Pharmaceutical Affairs Office + Pharmaceutical Inspection Office + Medical Devices Office + Pharmacy Practice Office + Cosmetics + Dietary Supplements Office + Food Office + Controlled Substances Office + Pharmacovigilance Centre + Clinical Trials Office + Reference Laboratories. The IFDA is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State.

Q.How does Iran's sanctions environment affect pharmaceutical market access?+

Iran operates under substantial US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance — this is the most operationally significant feature of Iranian pharmaceutical market access. The humanitarian-exemption General Licenses (notably US OFAC General License 8) permit medicines + medical devices + cosmetics + food transactions but require substantial financial-channel compliance (typically via Swiss Humanitarian Trade Arrangement or analogous structures), insurance, shipping, banking + due-diligence frameworks. The sanctions environment has driven substantial Iranian-domestic-manufacturing self-sufficiency policy (~97% domestic volume + ~70% domestic value coverage historically) + substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Pakistan + Afghanistan + Central Asian trade-partner reorientation. Foreign manufacturers + sponsors targeting Iran require substantial sanctions-environment compliance planning including humanitarian-exemption General License qualification + financial-channel arrangements + insurance + shipping + banking + due-diligence frameworks.

Q.How long does IFDA registration take?+

Standard timelines: new drug registration 270-360 calendar days; generic registration 180-270 calendar days; biosimilar registration 270-360 calendar days; vaccine registration 180-360 calendar days; ATMP registration 270-360 calendar days; SRA + WHO PQ reliance substantially reduced subject to sanctions-environment compliance; WHO PQ programme participation for Iranian-domestic manufacturers; Local-Industry-Protected Status pathway with IFDA + Syndicate of Iranian Pharmaceutical Industries coordinated review; trade-partner reliance with Roszdravnadzor + NMPA + CDSCO + TİTCK + DRAP substantially reduced; Variations 30-180 calendar days; Clinical Trial Application 60-90 calendar days; Compassionate Use + Named Patient expedited; Orphan Drug Designation; Pricing + Insurance Reimbursement Coordination parallel review post-registration. Sanctions-environment compliance planning + PIC/S Member mutual-recognition + EMA + SRA + WHO PQ reliance + Local-Industry-Protected Status pathway + trade-partner reliance are essential acceleration strategies for sponsors targeting Iran.

Q.What is the significance of Iran's PIC/S Member status (since 2018)?+

IFDA PIC/S Member status (since 2018) is one of the most operationally significant IFDA capabilities. PIC/S Membership enables substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance. This substantially reduces GMP-inspection burden + cost + timeline for foreign manufacturers operating Iranian-domestic facilities + for Iranian-domestic manufacturers (notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines) exporting to PIC/S Member markets. PIC/S Member status enables substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product issuance for substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa markets.

Q.Is the IFDA part of PIC/S + WHO PIDM + WHO PQ?+

Yes — IFDA is a PIC/S Member (since 2018) — one of the most operationally significant IFDA capabilities subject to sanctions-environment compliance; a WHO PIDM Member contributing substantial ADR data to VigiBase via Uppsala Monitoring Centre; a WHO PQ programme participant enabling substantial UN-agency humanitarian procurement + LMIC market access via Iranian-domestic manufacturers notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines; ECO Member State (10 Member States — Iran + Türkiye + Pakistan + Afghanistan + Azerbaijan + Kazakhstan + Kyrgyzstan + Tajikistan + Turkmenistan + Uzbekistan); ICH Observer; substantial WHO EMRO cooperation; substantial bilateral cooperation with Russian Roszdravnadzor + Chinese NMPA + Indian CDSCO + Turkish TİTCK + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian + Caucasus regulators; ICDRA + EMRO + IMDRF + IPRP + IGBA participation.

Q.What's distinctive about Iran's pharmaceutical environment as a regional biosimilar + vaccine hub?+

Iran's pharmaceutical environment is uniquely characterised by: substantial regional pharmaceutical-manufacturing hub status — ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical; substantial biotechnology + biosimilar industry — Cinnagen is one of the largest biosimilar manufacturers in EMRO + one of the substantial global biosimilar manufacturers, AryoGen Pharmed + Pooyesh Darou + Samenpharmed + Orchid Pharmed substantial capacity; substantial vaccine-manufacturing capacity via Razi Vaccine and Serum Research Institute (Karaj) + Pasteur Institute of Iran (Tehran) covering BCG + DTP + measles + rubella + hepatitis B + COVID-19 vaccines; substantial Royan Institute stem-cell + reproductive-biology + ATMP research capacity; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions with humanitarian-exemption General Licenses driving substantial domestic-manufacturing self-sufficiency + EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Pakistan + Afghanistan + Central Asian trade-partner reorientation; PIC/S Member status (since 2018); WHO PQ programme participation; ECO Member State; Persian (Farsi) labelling; Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability requirements. For foreign manufacturers, Iran is one of the most operationally significant pharmaceutical regulators globally for biosimilar + vaccine + ATMP partnership + EMRO + Central Asian + EAEU + Belt and Road market access via Iranian-localised production + PIC/S Member mutual-recognition + WHO PQ programme participation + sanctions-environment compliant pathways.

IFDA (Iran)

How does IFDA (Iran) apply to your shop floor?

01What the Iran FDA actually is

02Iranian pharmaceutical regulatory framework

03Drug + biological registration pathways at the IFDA

04IFDA Reference Laboratories + GMP Inspection + PIC/S Member capability

05Medical Device + IVD + Cosmetic + Dietary Supplement Registration

06IFDA Pharmacovigilance + Iranian ADR Centre

07IFDA international engagement

08Common IFDA registration issues + missteps

09How V5 Ultimate supports IFDA readiness

Frequently asked questions

Primary sources

Further reading

Next step

IFDA (Iran)

How does IFDA (Iran) apply to your shop floor?

01What the Iran FDA actually is

02Iranian pharmaceutical regulatory framework

03Drug + biological registration pathways at the IFDA

04IFDA Reference Laboratories + GMP Inspection + PIC/S Member capability

05Medical Device + IVD + Cosmetic + Dietary Supplement Registration

06IFDA Pharmacovigilance + Iranian ADR Centre

07IFDA international engagement

08Common IFDA registration issues + missteps

09How V5 Ultimate supports IFDA readiness

Frequently asked questions

Primary sources

Further reading

Next step